GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » Sale Of Investment

Nabriva Therapeutics (STU:NTY) Sale Of Investment : €0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Sale Of Investment?

Nabriva Therapeutics's sale of investment for the three months ended in Jun. 2023 was €0.00 Mil. It means Nabriva Therapeutics gained €0.00 Mil from selling investments. Nabriva Therapeutics's sale of investment for the trailing twelve months (TTM) ended in Jun. 2023 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Mar. 2023 ), Nabriva Therapeutics gained the same money from selling investments in Jun. 2023 (€0.00 Mil).


Nabriva Therapeutics Sale Of Investment Historical Data

The historical data trend for Nabriva Therapeutics's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Sale Of Investment Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nabriva Therapeutics Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nabriva Therapeutics Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (STU:NTY) Business Description

Traded in Other Exchanges
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines